SeluDex: A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adult patients with 2nd relapsed precursor B- or T-ALL

Medicine & Life Sciences

1. AZD 6244 100%
2. Precursor Cell Lymphoblastic Leukemia-Lymphoma 59%
3. Dexamethasone 55%
4. Pediatrics 38%
5. T-Lymphoid Precursor Cells 16%
6. Therapeutics 9%
7. Bayes Theorem 9%
8. Paris 9%
9. B-Lymphoid Precursor Cells 9%
10. Denmark 8%
11. Netherlands 7%
12. Italy 7%
13. France 7%
14. Progression-Free Survival 6%
15. Germany 6%
16. Mutation 6%
17. Publications 6%
18. Survival Rate 5%
19. Steroids 5%
20. Medical Ethics 5%